成人接种蛋基灭活或重组流感疫苗后针对血凝素和神经氨酸酶的抗体应答
在18-64岁成人随机试验中比较2022-2023四价重组流感疫苗(RIV)与标准剂量蛋基灭活疫苗(SD-IIV)的体液免疫;RIV组针对细胞培养A型和B/Yamagata病毒的抗HA应答高2倍,SD-IIV未诱导针对哺乳细胞培养病毒的NA抑制抗体但可增强针对蛋培养病毒的NA抗体。
要点
- RIV组抗HA中和抗体滴度较SD-IIV组高2倍(细胞培养A型和B/Yamagata病毒)。
- SD-IIV组未出现针对哺乳细胞培养病毒的NA抑制抗体升高。
- SD-IIV组针对蛋培养N1和N2抗原的ELLA GMTs分别有13%和37%达≥4倍升高。
核心结论
- RIV受者针对HA的抗体应答更强。
- SD-IIV未诱导针对哺乳细胞培养病毒的有意义NA抑制抗体应答,但可增强针对蛋培养病毒的抗体。
- 评估疫苗接种体液应答时,应考虑从细胞培养病毒中获取NA抗原。
研究设计与样本
- 随机试验比较2022-2023四价RIV与标准剂量IIV在18-64岁成人中的免疫应答;亚组在接种前、接种后1个月和6个月采集血清。
- 采用单周期复制IRINA测定针对细胞基和蛋基疫苗参考病毒及代表性流行病毒的中和滴度,ELLA评估N1和N2的NA抑制应答,ELISA测量N2结合应答。
主要发现
- RIV组针对细胞基A型和B/Yamagata病毒的抗HA应答较SD-IIV组高2倍;针对细胞基B/Victoria病毒的差异无统计学意义。
- 接种后血清对流行病毒的反应与对细胞基疫苗病毒相当,但对A(H1N1)pdm09反应降低2-6倍。
- 与HI抗体相比,中和抗体对多数疫苗病毒消退更快。
- SD-IIV组针对哺乳细胞培养病毒的NA抑制抗体无升高;针对蛋培养N1和N2抗原的ELLA GMTs分别有13%和37%达≥4倍升高,尽管NA序列无变化。
- 基线蛋/细胞滴度比N1为1.3、N2为4.2,接种后SD-IIV组约增加2倍而RIV组未增加。
关键数值与推荐
- RIV组抗HA应答较SD-IIV组高2倍(细胞基A型和B/Yamagata病毒)。
- SD-IIV组针对蛋培养N1抗原ELLA GMTs有13%达≥4倍升高,N2抗原有37%达≥4倍升高。
- 基线蛋/细胞滴度比N1为1.3、N2为4.2。
- 接种后对A(H1N1)pdm09中和滴度较细胞基疫苗病毒降低2-6倍。
临床怎么用
- 解读流感疫苗免疫原性时需区分HA与NA抗体应答及抗原来源(蛋基vs细胞基)。
- 评估NA抗体应答宜采用细胞培养病毒制备的NA抗原,避免蛋适应偏倚。
- RIV可能提供更强的HA靶向抗体应答,但需结合疫苗有效性数据综合判断。
局限性
- 原文未报告6个月后抗体消退的具体数值。
- 原文未报告疫苗有效性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antibodies to hemagglutinin (HA) and neuraminidase (NA) are independent surrogates of protection from influenza yet only HA content is standardized in vaccines. Egg-based inactivated influenza vaccines (IIV) contain HA and NA from egg-adapted viruses. Recombinant influenza vaccines (RIV) solely include HA without egg-adapted modifications. Humoral responses to both HA and NA can provide valuable insights into vaccine effectiveness. METHODS: In a randomized trial comparing 2022-2023 quadrivalent RIV and standard dose (SD) IIV among adults aged 18-64 years, a subgroup of participants had sera collected pre-vaccination, 1-, and 6-months post-vaccination. Neutralization titers were determined for both cell- and egg-based vaccine reference viruses and representative circulating viruses using single cycle replication-based IRINA. NA-inhibiting responses to N1 and N2 were evaluated using ELLA; ELISA was used to measure N2-binding response. RESULTS: Anti-HA responses to cell-based type A and B/Yamagata viruses were two-fold higher among RIV versus SD-IIV recipients; the difference in response to cell-based B/Victoria virus was not statistically significant. Compared to responses to cell-based vaccine viruses, post-vaccination sera reacted comparably to circulating viruses, except to A(H1N1)pdm09 (2-6-fold reduction). Compared to HI antibodies, neutralizing antibodies waned faster to most vaccine viruses. SD-IIV recipients showed no rise in NA-inhibiting antibodies to mammalian cell-grown viruses. Conversely, there was a ≥ 4-fold rise in ELLA GMTs to N1 (13%) and N2 (37%) antigens that were prepared in eggs, despite no changes in NA sequences. Baseline egg/cell titer ratios were 1.3 for N1 and 4.2 for N2 antigens, and they increased by approximately 2-fold after vaccination in SD-IIV but not RIV recipients. CONCLUSION: HA-targeting antibody responses were more robust in RIV-recipients. SD-IIV did not elicit meaningful NA-inhibiting antibody responses to viruses grown in mammalian cells but did boost antibodies to egg-grown viruses. Sourcing NA antigens from cell-grown viruses should be considered when assessing humoral responses to vaccination.
引用
- Mishin VP, Patel MC, Gao R, et al. Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18-64 years. Vaccine. 2026. PMID: 42945702. doi:10.1016/j.vaccine.2026.129281
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。